Ultragenyx Pharmaceutical Inc. Stock 12‑Month Price Target Cut to $52, Implies 97% Upside
Analyst estimates for Ultragenyx Pharmaceutical Inc. show its 12-month average price target cut to $52 from $52.84. The range is $27 to $96 per share, based on 18 analysts. Using the Aug. 13 close, the target implies about 97% upside. The consensus rating remains “Buy” with 16 Buys, 3 Holds, and 0 Sells.
How this was made
The 30-second read
Why it matters
Consensus average target is slightly lower, but the rating remains Buy (16 Buys, 3 Holds, 0 Sells). Without a new underlying catalyst, the trading signal is mostly sentiment/positioning rather than fundamentals.
Market read
Traders may adjust expectations for RARE based on the consensus target cut, but the article lacks new operational or clinical information.
What to watch
The article does not state which analysts changed targets, why they changed them, or whether any new clinical or financial data drove the revision.
Background
The piece summarizes FactSet analyst consensus for Ultragenyx’s 12-month price target and rating distribution.
Ticker impact
The article says Ultragenyx (RARE) average 12-month price target fell from $52.84 to $52, with a $27 to $96 range.
Near-term: limited directional impact unless traders treat the target cut as a proxy for deteriorating fundamentals; otherwise likely fades.
This is a FactSet-derived consensus target update without any new trial, guidance, or corporate event disclosed in the text.
Market effects
Minimal. Target revisions can affect biotech sentiment, but no sector-wide regulatory or clinical catalyst is mentioned.
None indicated; the story is company-specific analyst consensus data.
None indicated.
Counterpoint
A lower average target may not imply fundamental deterioration because the consensus rating stays Buy and the range remains wide ($27 to $96).
Key entities
- companyUltragenyx Pharmaceutical Inc.
Subject of the article; analyst consensus price target and rating distribution are summarized.
